comparemela.com

Latest Breaking News On - Independent data monitoring committee - Page 9 : comparemela.com

Acurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2B Clinical Trial in CDI Patients

Acurx Pharmaceuticals, Inc. announced positive comparative microbiology and microbiome data for ibezapolstat, its lead antibiotic candidate, from the Company s recently completed Phase 2b clinical.

United statesCompany scientific advisory boardData monitoring committeeAcurx pharmaceuticals incTrial oversight committeeEuropean medicines agencyAcurx pharmaceuticalsFirst quarterExtended clinical cureScientific advisory boardClinical cureModified intentTreat populationPer protocol populationPrescribing informationIndependent data monitoring committee

Acurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients

Ibezapolstat outperformed vancomycin showing eradication of fecal C. difficile at Day 3 of treatment in 15 of 16 treated patients (94%), versus vancomycin.

United statesUniversity of houstonDavidp luciKevin gareyRobertj delucciaAcurx pharmaceuticalsSociety or healthcare epidemiology of americaCompany phCompany scientific advisory boardExchange commissionData monitoring committeeUniversity of houston college pharmacyTrial oversight committeeEuropean medicines agencyDrug administrationExchange commission on form

Menopause Management: Bayer s Non-Hormonal Treatment Option Shows Efficacy In Trial - Bayer (OTC:BAYRY)

Monday, Bayer AG (OTC: BAYRY (OTC: BAYZF) 

Wikimedia commonsBayer agbayzfannouncedBayerand asklepios biopharmaceutical incData monitoring committeeLegal victory for bayerRoundup lawsuit ends five trial losingIndependent data monitoring committee

Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok® Therapeutic to Salvage Catheters

Topline results expected 2Q 2024 Study enrolled a total of 241 patients; 109 catheter failures observed First-and-only antibiotic lock solution in development to salvage catheters in patients with.

United statesCitius pharmaIlanit allenGreg salsburgLeonard mazurUniversity of texas md anderson cancer centerCompany nasdaqCitius pharmaceuticals incSecurities exchangeExchange commissionData monitoring committeeInfectious diseases society of americaCitius pharmaceuticalsChief executive officerIndependent data monitoring committeeLok phase

Sanofi stops development of tusamitamab ravtansine

Sanofi stops development of tusamitamab ravtansine
europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.

Dietmar bergerData monitoring committeeHead of development at sanofiIndependent data monitoring committeeChief medical officer

vimarsana © 2020. All Rights Reserved.